With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...
Advances in radiotherapy are rapidly transforming how prostate cancer is treated, offering patients more precise, less invasive options that can fit more easily around everyday life ...
A clinical trial that could validate the halving of the recovery pathway for postoperative cardiac patients would be a ...
A 42-year-old pharmacist diagnosed with stage 3A lung cancer involving major blood vessels made a rapid recovery after ...
Data Supported the FDA Approval of the Zenflow Spring® Implant and Delivery System for BPHAdditional presented data highlights patient ...
Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...
In the second piece of our investigation on local enhanced services, Harry Hetherington looks at why GPs take on unfunded LES work ...
Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- ...
High Intensity Focused Ultrasound Market · GlobeNewswire Inc. Dublin, May 20, 2026 (GLOBE NEWSWIRE) -- The "High Intensity ...
In times of uncertainty, it is comforting to have in your portfolio some substantial, growing companies with leading market ...
Two urologists have left or are leaving, putting cancer patients at risk of longer wait times and limited access to care.
Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results